Key Segmentation
By Test Type
-
NS1 Antigen Test
-
IgM Antibody Test
-
IgG Antibody Test
-
RT-PCR Test
By Technology
-
ELISA
-
Rapid Diagnostic Tests (RDTs)
-
PCR
-
Others
By Product Type
-
Test Kits
-
Instruments
-
Reagents & Consumables
-
Others
By End-User
-
Hospitals
-
Diagnostic Laboratories
-
Public Health Laboratories
-
Research Institutes
By Sample Type
-
Blood
-
Serum
-
Plasma
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Asia Pacific dominated the market due to advanced healthcare infrastructure and strong diagnostic adoption, and also it is the fastest-growing region, driven by high disease burden, expanding healthcare access, and increasing testing volumes.
NS1 Antigen Test dominated with a 34.25% share in 2025, while RT-PCR Test accounted for 6.74% and remains widely used for early detection across healthcare settings.
Growth is driven by rising dengue prevalence, increasing demand for early and accurate diagnosis, expansion of diagnostic infrastructure, adoption of rapid and molecular testing technologies, and government-led disease surveillance programs.
The market is valued at USD 594.76 Million in 2025 and is projected to reach USD 971.11 Million by 2035.
The Dengue Testing Market is projected to grow at a CAGR of 5.08% during 2026–2035.